{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:42:16Z","timestamp":1789040536924,"version":"build-2803163510"},"reference-count":33,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Systemic lupus erythematosus (SLE) is a chronic and complex multisystem autoimmune disease with high mortality. Telitacicept is a new strategy for the treatment of SLE, inhibiting the maturity, proliferation and differentiation of B cells, and thus, reduces disease activity. However, the effectiveness and safety of telitacicept in patients with SLE are not yet established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Five English databases (Pubmed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, Cumulative Index of Nursing and Allied Health Literature) and four Chinese databases (China National Knowledge Infrastructure, Wanfang Data, China Science and Technology Journal Database and Sinomed) will be searched from database inception to 1 June 2025. Two investigators will independently conduct study selection, data extraction and quality assessment. Outcomes include disease activity, incidence of flares, organ damage, several immune-related laboratory parameters and adverse events. Risk ratio with 95% CI and mean difference or standardised mean difference will be used as measures of effect sizes, in order to pool the data using either a random-effect model or fixed-effect model according to the heterogeneity of studies. Subgroup analysis and sensitivity analysis will be performed to explore the source of heterogeneity and evaluate the robustness of the results. We will use the Risk of Bias 2 tool and Risk of Bias In Non-Randomized Studies of Interventions tools to assess the quality of the included studies, and use the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system to assess the certainty of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>No ethical approval is required since this review is based on previously published studies. The findings of this study will be presented at international conferences or published in a peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024558180.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-090646","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:10:24Z","timestamp":1752657024000},"page":"e090646","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Telitacicept for systemic lupus erythematosus: protocol of a systematic review and meta-analysis"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5073-1528","authenticated-orcid":false,"given":"Xiangge","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China"},{"name":"College of Pediatrics, Henan University of Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0857-9171","authenticated-orcid":false,"given":"Peidong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China"},{"name":"College of Pediatrics, Henan University of Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China"},{"name":"College of Pediatrics, Henan University of Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China"},{"name":"College of Pediatrics, Henan University of Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China"},{"name":"College of Pediatrics, Henan University of Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2025121401422862000_15.7.e090646.1","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202006020"},{"key":"2025121401422862000_15.7.e090646.2","doi-asserted-by":"crossref","DOI":"10.3390\/biom11070928","article-title":"Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus","volume":"11","author":"Yu","year":"2021","journal-title":"Biomolecules"},{"key":"2025121401422862000_15.7.e090646.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035"},{"key":"2025121401422862000_15.7.e090646.4","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/1744666X.2018.1538789","article-title":"Mortality in systemic lupus erythematosus: causes, predictors and interventions","volume":"14","author":"Ocampo-Piraquive","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2025121401422862000_15.7.e090646.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.30277"},{"key":"2025121401422862000_15.7.e090646.6","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults","volume":"393","author":"Durcan","year":"2019","journal-title":"The Lancet"},{"key":"2025121401422862000_15.7.e090646.7","doi-asserted-by":"crossref","DOI":"10.1186\/ar2764","article-title":"Predictors of major infections in systemic lupus erythematosus","volume":"11","author":"Ruiz-Irastorza","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2025121401422862000_15.7.e090646.8","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12660"},{"key":"2025121401422862000_15.7.e090646.9","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.240"},{"key":"2025121401422862000_15.7.e090646.10","doi-asserted-by":"crossref","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2025121401422862000_15.7.e090646.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2013.04.003"},{"key":"2025121401422862000_15.7.e090646.12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cyto.2018.11.008","article-title":"BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus","volume":"114","author":"Salazar-Camarena","year":"2019","journal-title":"Cytokine"},{"key":"2025121401422862000_15.7.e090646.13","first-page":"1671","article-title":"Telitacicept: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025121401422862000_15.7.e090646.14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today"},{"key":"2025121401422862000_15.7.e090646.15","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493"},{"key":"2025121401422862000_15.7.e090646.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854"},{"key":"2025121401422862000_15.7.e090646.17","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2025121401422862000_15.7.e090646.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025121401422862000_15.7.e090646.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.06.011"},{"key":"2025121401422862000_15.7.e090646.20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"key":"2025121401422862000_15.7.e090646.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.06.015"},{"key":"2025121401422862000_15.7.e090646.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.05.005"},{"key":"2025121401422862000_15.7.e090646.23","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-022-01091-9","article-title":"Sex and out-of-hospital cardiac arrest survival: a systematic review","volume":"12","author":"Lakbar","year":"2022","journal-title":"Ann Intensive Care"},{"key":"2025121401422862000_15.7.e090646.24","unstructured":"Page M SJ , Higgins J , On behalf of the development group for ROB-ME . The rob-me (risk of bias due to missing evidence) tool: a new tool for assessing reporting biases in evidence syntheses. Abstracts of the 25th Cochrane Colloquium, Edinburgh, UK Cochrane Database of Systematic Reviews; 2018"},{"key":"2025121401422862000_15.7.e090646.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-062046","article-title":"PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"Luo","year":"2022","journal-title":"BMJ Open"},{"key":"2025121401422862000_15.7.e090646.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-022-02146-5","article-title":"All-cause mortality after major gastrointestinal bleeding among patients receiving direct oral anticoagulants: a protocol for a systematic review and meta-analysis","volume":"11","author":"Chornenki","year":"2022","journal-title":"Syst Rev"},{"key":"2025121401422862000_15.7.e090646.27","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12817"},{"key":"2025121401422862000_15.7.e090646.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2025121401422862000_15.7.e090646.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020400","article-title":"Acupuncture for constipation in patients with stroke: protocol of a systematic review and meta-analysis","volume":"8","author":"Zhai","year":"2018","journal-title":"BMJ Open"},{"key":"2025121401422862000_15.7.e090646.30","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s10157-024-02501-x","article-title":"Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study","volume":"28","author":"Huang","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"2025121401422862000_15.7.e090646.31","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001074","article-title":"Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study","volume":"10","author":"Jin","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2025121401422862000_15.7.e090646.32","first-page":"94","article-title":"The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study","volume":"32","author":"Chen","year":"2023","journal-title":"Lupus (Los Angel)"},{"key":"2025121401422862000_15.7.e090646.33","first-page":"998","article-title":"Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before\u2013after trial","volume":"31","author":"Sun","year":"2022","journal-title":"Lupus (Los Angel)"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-090646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:42:37Z","timestamp":1765705357000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-090646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,16]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2024-090646"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-090646","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}